{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:04:50Z","timestamp":1784531090225,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["R016010006"],"award-info":[{"award-number":["R016010006"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["R016010005"],"award-info":[{"award-number":["R016010005"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["R016034008"],"award-info":[{"award-number":["R016034008"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biopha.2026.119731","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T20:23:47Z","timestamp":1783369427000},"page":"119731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma"],"prefix":"10.1016","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2205-6905","authenticated-orcid":false,"given":"Thaweesak","family":"Chieochansin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornkan","family":"Choomee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7831-2475","authenticated-orcid":false,"given":"Napat","family":"Angkathunyakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Pongpaibul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prawat","family":"Kositamongkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prawej","family":"Mahawithitwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-0528","authenticated-orcid":false,"given":"Chutwichai","family":"Tovikkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wethit","family":"Dumronggittigule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pholasith","family":"Sangserestid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-2458","authenticated-orcid":false,"given":"Charnwit","family":"Assawasirisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyut","family":"Sirivatanauksorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-5927","authenticated-orcid":false,"given":"Pa-thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2026.119731_bib1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.celrep.2017.03.059","article-title":"hepatocellular carcinomas originate predominantly from hepatocytes and benign lesions from hepatic progenitor cells","volume":"19","author":"Tummala","year":"2017","journal-title":"Cell. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2026.119731_bib2","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119731_bib3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2147\/JHC.S347959","article-title":"Perspectives on the underlying etiology of HCC and its effects on treatment outcomes","volume":"10","author":"Ito","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"Suppl 1(Suppl 1)","key":"10.1016\/j.biopha.2026.119731_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119731_bib5","first-page":"1","article-title":"Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification","volume":"149","author":"Chidambaranathan-Reghupaty","year":"2021","journal-title":"Adv. Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2026.119731_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112798","article-title":"Emerging therapies for hepatocellular carcinoma (HCC)","volume":"14","author":"Chakraborty","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.biopha.2026.119731_bib7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119731_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.17998\/jlc.2022.03.04","article-title":"Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma","volume":"22","author":"Lee","year":"2022","journal-title":"J. Liver Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2026.119731_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041310","article-title":"Management of hepatocellular carcinoma in decompensated cirrhotic patients: a comprehensive overview","volume":"15","author":"Tampaki","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119731_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2147\/JHC.S300182","article-title":"Hepatocellular carcinoma: an overview of the changing landscape of treatment options","volume":"8","author":"Koulouris","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.biopha.2026.119731_bib11","article-title":"Downstaging therapies for unresectable hepatocellular carcinoma prior to hepatic resection: a systematic review and meta-analysis","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119731_bib12","first-page":"855","article-title":"Comparison of five staging systems in predicting the survival rate of patients with hepatocellular carcinoma undergoing trans-arterial chemoembolization therapy","volume":"15","author":"Chen","year":"2018","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.biopha.2026.119731_bib13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/hep.27443","article-title":"Prognosis of untreated hepatocellular carcinoma","volume":"61","author":"Giannini","year":"2015","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.biopha.2026.119731_bib14","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119731_bib15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1373\/clinchem.2016.258988","article-title":"Immunotherapy using chimeric antigen receptor-engineered T cells: a novel cellular therapy with important implications for the clinical laboratory","volume":"65","author":"Thibodeaux","year":"2019","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2026.119731_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.biopha.2026.119731_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric antigen receptors modified T-cells for cancer therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.biopha.2026.119731_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/cr.2016.154","article-title":"Driving gene-engineered T cell immunotherapy of cancer","volume":"27","author":"Johnson","year":"2017","journal-title":"Cell. Res."},{"issue":"7655","key":"10.1016\/j.biopha.2026.119731_bib19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2026.119731_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2026.119731_bib21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119731_bib22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1674","article-title":"CAR T-cell therapy in hematologic malignancies: a voyage in progress","volume":"107","author":"Holstein","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"16","key":"10.1016\/j.biopha.2026.119731_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168996","article-title":"CAR T-cell therapy in hematological malignancies","volume":"22","author":"Haslauer","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119731_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-020-00890-6","article-title":"Gene modification strategies for next-generation CAR T cells against solid cancers","volume":"13","author":"Tian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119731_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119731_bib26","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2026.119731_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1489649","article-title":"CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119731_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109333","article-title":"Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection","volume":"118","author":"Hu","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.biopha.2026.119731_bib29","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.biopha.2026.119731_bib30","doi-asserted-by":"crossref","DOI":"10.1063\/5.0073746","article-title":"Engineering CAR T cells for enhanced efficacy and safety","volume":"6","author":"Wu","year":"2022","journal-title":"APL Bioeng."},{"key":"10.1016\/j.biopha.2026.119731_bib31","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and safety of CD28- or 4-1BB-based CD19 CAR-T cells in B cell acute lymphoblastic leukemia","volume":"18","author":"Zhao","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.biopha.2026.119731_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.539654","article-title":"4-1BB signaling boosts the anti-tumor activity of CD28-incorporated 2(nd) generation chimeric antigen receptor-modified T cells","volume":"11","author":"Dai","year":"2020","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119731_bib33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119731_bib34","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1073\/pnas.91.8.3260","article-title":"Activation-dependent phosphorylation of the T-lymphocyte surface receptor CD28 and associated proteins","volume":"91","author":"Hutchcroft","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2026.119731_bib35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev.iy.11.040193.001203","article-title":"The role of the CD28 receptor during T cell responses to antigen","volume":"11","author":"Linsley","year":"1993","journal-title":"Annu. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119731_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003354","article-title":"4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells","volume":"9","author":"Roselli","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2026.119731_bib37","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.4049\/jimmunol.162.9.5037","article-title":"Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal","volume":"162","author":"Takahashi","year":"1999","journal-title":"J. Immunol."},{"issue":"625","key":"10.1016\/j.biopha.2026.119731_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci. Signal."},{"issue":"3","key":"10.1016\/j.biopha.2026.119731_bib39","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","article-title":"Jr., CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo","volume":"119","author":"Song","year":"2012","journal-title":"Blood"},{"issue":"Pt B","key":"10.1016\/j.biopha.2026.119731_bib40","article-title":"Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells","volume":"89","author":"Sangsuwannukul","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119731_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100971","article-title":"GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction","volume":"14","author":"Sujjitjoon","year":"2021","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119731_bib42","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1038\/s41598-021-85747-9","article-title":"Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma","volume":"11","author":"Supimon","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119731_bib43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10549-020-06032-3","article-title":"Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy","volume":"186","author":"Luangwattananun","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2026.119731_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111631","article-title":"Cytotoxicity of fourth-generation anti-Trop2 CAR-T cells against breast cancer","volume":"129","author":"Somboonpatarakun","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119731_bib45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3748\/wjg.v22.i1.275","article-title":"Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma","volume":"22","author":"Haruyama","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2026.119731_bib46","article-title":"Glypican-3: a novel and promising target for the treatment of hepatocellular carcinoma","volume":"12","author":"Zheng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119731_bib47","doi-asserted-by":"crossref","DOI":"10.1053\/j.semnuclmed.2025.09.004","article-title":"Glypican-3: novel theranostic agent for hepatocellular carcinoma","author":"Filippi","year":"2025","journal-title":"Semin. Nucl. Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119731_bib48","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1217868110","article-title":"Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma","volume":"110","author":"Feng","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.biopha.2026.119731_bib49","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000022","article-title":"Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC","volume":"7","author":"Kolluri","year":"2023","journal-title":"Hepatol. Commun."},{"issue":"8","key":"10.1016\/j.biopha.2026.119731_bib50","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1053\/j.gastro.2020.02.011","article-title":"Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice","volume":"158","author":"Li","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2026.119731_bib51","first-page":"690","article-title":"Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma","volume":"7","author":"Jiang","year":"2016","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.biopha.2026.119731_bib52","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119731_bib53","article-title":"Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains","volume":"11","author":"Wutti-In","year":"2021","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119731_bib54","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"issue":"12","key":"10.1016\/j.biopha.2026.119731_bib55","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/bjc.2015.92","article-title":"Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area","volume":"112","author":"Sideras","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2026.119731_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115801","article-title":"Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review","volume":"22","author":"Oura","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2026.119731_bib57","article-title":"CAR-T cells in solid tumors: challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.biopha.2026.119731_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.657868","article-title":"Chimeric antigen receptor T cells targeting integrin \u03b1v\u03b26 expressed on cholangiocarcinoma cells","volume":"11","author":"Phanthaphol","year":"2021","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119731_bib59","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00262-020-02838-8","article-title":"CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors","volume":"70","author":"Chen","year":"2021","journal-title":"Cancer immunology immunotherapy CII"},{"issue":"8","key":"10.1016\/j.biopha.2026.119731_bib60","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/CJI.0b013e3181ee238f","article-title":"Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells","volume":"33","author":"Roberts","year":"2010","journal-title":"J. Immunother."},{"issue":"6","key":"10.1016\/j.biopha.2026.119731_bib61","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119731_bib62","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/j.ymthe.2020.07.023","article-title":"A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-Seq","volume":"28","author":"Boroughs","year":"2020","journal-title":"Molecular therapy journal American Society Gene Therapy"},{"issue":"26","key":"10.1016\/j.biopha.2026.119731_bib63","first-page":"3153","article-title":"Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction","volume":"141","author":"Selli","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.biopha.2026.119731_bib64","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119731_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050602","article-title":"Hypoxia selectively impairs CAR-T cells In vitro","volume":"11","author":"Berahovich","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2026.119731_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000676","article-title":"Inhibition of TGF-\u03b2-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer","volume":"8","author":"St\u00fcber","year":"2020","journal-title":"J. Immunother. Cancer"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:31:09Z","timestamp":1784529069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226007675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":66,"alternative-id":["S0753332226007675"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119731","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119731"}}